Clinical trials ophthalmic drugs

Participation in another ophthalmic clinical trial of use or any other investigational new drugs within 12 weeks prior to the start of study treatment Active hepatitis or clinically significant liver disease Porphyria or other porphyrin sensitivity Prior photodynamic therapy for CNV... 

A reduction of the comeal sensitivity in rabbits should, therefore, not be considered prohibitive for the further development of ophthalmic drugs for topical use in man, but induce special consideration to this parameter during clinical trials. 

---